Evogene reports Q4 EPS 6c vs. ($1.30) last year

Reports Q4 revenue $1.6M vs. $0.6M last year. CEO Ofer Haviv stated: “2024 was a year of topline growth, reduction in cash use and value creation. We expect this trend to continue. I would like to share with you Evogene’s (EVGN) prospects for the near future,” Mr. Haviv continued. “Evogene intends to direct its efforts by focusing further on the use of our ChemPass AI tech-engine in the field of AI powered drug discovery…With regard to Evogene’s subsidiaries our intention is to focus on creating exit events for part of our subsidiaries…Evogene will also support subsidiaries’ efforts in their strategic fundraising activities. Part of the funds will be used by the subsidiaries to finance the development of Evogene’s tech-engines according to their needs. These strategic guidelines are expected to strengthen Evogene’s financial position. Through focus on a single engine and implementation of our expense reduction plan, we expect to substantially lower expenses, and through exit events, dividends, and technology license payments, we anticipate enhancing Evogene’s financials.”